UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2026
Commission File Number: 001-40617
Regencell Bioscience Holdings Limited
(Registrant’s Name)
9/F Chinachem Leighton Plaza
29 Leighton Road
Causeway Bay, Hong Kong
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
EXHIBIT INDEX
| Exhibit No. |
|
Description of Exhibit |
| 99.1 |
|
Press Release – Regencell Bioscience Holdings Limited Announces Closing of Registered Direct Offering of Ordinary Shares |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: May 22, 2026
| |
Regencell Bioscience Holdings Limited |
| |
|
|
| |
By: |
/s/ Yat-Gai Au |
| |
Name: |
Yat-Gai Au |
| |
Title: |
Chief Executive Officer and |
| |
|
Chairman of the Board of Directors |
[Signature Page to Form
6-K]
Exhibit 99.1
Regencell Bioscience Holdings Limited Announces
Closing of Registered Direct Offering of Ordinary Shares
HONG KONG, May 22, 2026 – Regencell Bioscience
Holdings Limited (Nasdaq: RGC) (the “Company”) announced the closing of a registered direct offering (the “offering”)
of approximately $20.0 million led by a $19 million investment from a new fundamental institutional
investor with further participation from Univest Securities, LLC (“Univest”),
as previously announced on May 19, 2026.
Under the terms of the securities purchase agreement
in connection with the offering, the Company agreed to sell an aggregate of 985,222 ordinary shares, par value $0.00001 per share (the
“Ordinary Shares”) at a purchase price of $20.30 per Ordinary Share. The aggregate gross proceeds of the offering to the Company
were approximately $20.0 million.
Univest acted as the sole placement agent for
the offering.
The offering was made pursuant to a shelf registration
statement on Form F-3 (File No. 333-294722) which was filed with the U.S. Securities and Exchange Commission (the “SEC”) by
the Company on March 30, 2026 and became automatically effective upon filing on March 30, 2026. A prospectus supplement (File No. 333-294722)
and accompanying prospectus describing the terms of the offering were filed with the SEC by the Company on May 19, 2026 and are available
on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus
may be obtained by contacting Univest at info@univest.us, or by calling +1 (212) 343-8888.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy any securities of the Company, nor will there be any sales of such securities in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of such state or jurisdiction.
About Regencell Bioscience Holdings Limited
We are an early-stage bioscience company that
focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and
degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. Our goal is to save and improve the
lives of the patients, their families and caregivers and become a market leader for natural and holistic treatments for neurological disorders
globally.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify some of these forward-looking
statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,”
“continue” or other similar expressions. Statements that are not historical facts, including statements about the Company’s
beliefs and expectations, are forward-looking statements. Among other things, the business outlook from management in this press release,
as well as the Company’s strategic and operational plans, contain forward-looking statements. The Company may also make written
or oral forward-looking statements in its periodic reports to the SEC on Forms 20-F and Form 6-K, in its annual reports to shareholders,
in its and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking
statements involve inherent risks and uncertainties.
A number of factors could cause actual results
to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s
goals and strategies; the Company’s future business development, financial condition and results of operations; changes in the Company’s
expenditures; general economic and business conditions globally; and assumptions underlying or related to any of the foregoing.
Further information regarding these and other
risks is included in the Company’s annual report on Form 20-F and current report on Form 6-K and other documents filed with the
SEC. All information provided in this press release is as of the date hereof, and the Company does not undertake any obligation to update
any forward-looking statement, except as required under applicable laws.
CONTACT:
Regencell Bioscience Holdings Limited Investor Relations
James Chung
ir@rgcbio.com
SOURCE:
Regencell Bioscience Holdings Limited
